Conatus Pharmaceuticals (CNAT) Trading Down 6.3%

Conatus Pharmaceuticals Inc (NASDAQ:CNAT)’s share price was down 6.3% on Friday . The company traded as low as $2.56 and last traded at $2.67. Approximately 1,376,097 shares were traded during trading, an increase of 89% from the average daily volume of 727,249 shares. The stock had previously closed at $2.85.

A number of equities analysts recently weighed in on CNAT shares. HC Wainwright decreased their price objective on Conatus Pharmaceuticals from $14.00 to $8.00 and set a “buy” rating on the stock in a report on Monday. Roth Capital reissued a “buy” rating on shares of Conatus Pharmaceuticals in a report on Wednesday, February 13th. SunTrust Banks decreased their price objective on Conatus Pharmaceuticals to $12.00 and set a “buy” rating on the stock in a report on Thursday, December 6th. Oppenheimer set a $10.00 price objective on Conatus Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, December 6th. Finally, Zacks Investment Research raised Conatus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $1.50 price objective on the stock in a report on Tuesday, December 18th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company’s stock. Conatus Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $7.10.

The stock has a market capitalization of $83.37 million, a PE ratio of -4.53 and a beta of 3.36.

Conatus Pharmaceuticals (NASDAQ:CNAT) last posted its quarterly earnings results on Friday, March 8th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.01. Conatus Pharmaceuticals had a negative return on equity of 82.49% and a negative net margin of 53.62%. The business had revenue of $7.41 million for the quarter, compared to analyst estimates of $8.63 million. On average, equities analysts forecast that Conatus Pharmaceuticals Inc will post -0.38 earnings per share for the current fiscal year.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Geode Capital Management LLC grew its position in Conatus Pharmaceuticals by 19.4% during the 4th quarter. Geode Capital Management LLC now owns 208,346 shares of the biotechnology company’s stock worth $360,000 after acquiring an additional 33,827 shares during the last quarter. Sofinnova Investments Inc. grew its position in Conatus Pharmaceuticals by 18.4% during the 4th quarter. Sofinnova Investments Inc. now owns 638,197 shares of the biotechnology company’s stock worth $1,104,000 after acquiring an additional 99,282 shares during the last quarter. D. E. Shaw & Co. Inc. grew its position in Conatus Pharmaceuticals by 50.4% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 62,163 shares of the biotechnology company’s stock worth $108,000 after acquiring an additional 20,826 shares during the last quarter. Two Sigma Investments LP grew its position in Conatus Pharmaceuticals by 761.1% during the 4th quarter. Two Sigma Investments LP now owns 250,085 shares of the biotechnology company’s stock worth $433,000 after acquiring an additional 221,044 shares during the last quarter. Finally, Creative Planning bought a new position in Conatus Pharmaceuticals during the 4th quarter worth approximately $38,000. Institutional investors and hedge funds own 27.41% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This article was first published by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this article on another domain, it was copied illegally and reposted in violation of United States and international copyright & trademark laws. The correct version of this article can be read at https://sportsperspectives.com/2019/03/15/conatus-pharmaceuticals-cnat-trading-down-6-3.html.

About Conatus Pharmaceuticals (NASDAQ:CNAT)

Conatus Pharmaceuticals Inc, a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for patients with portal hypertension; for patients liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function.

Read More: Quiet Period

Receive News & Ratings for Conatus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.